• The clinical study report published
• A financing rpund expected in Q2
• Our model suggests a fair value of SEK 16.29 per share

The clinical study report of Lipum’s phase I study with SOL-116 was published in April. In line with the topline data, the complete findings strongly support further clinical development of the drug candidate. The company is now planning the phase II study in rheumatoid arthritis (RA), expected to start in Q1 2026. Essential for the development is securing the funding. By the end of Q1, Lipum’s cash holdings amounted to MSEK 4.26. We anticipate a rights issue being announced shortly.
Read the full report here.